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Abstract. 
 
Although the number of pathologies known 
to arise from the inappropriate folding of proteins con-
tinues to grow, mechanisms underlying the recognition 
and ultimate disposition of misfolded polypeptides re-
main obscure. For example, how and where such sub-
strates are identified and processed is unknown. We re-
port here the identification of a specific subcellular 
structure in which, under basal conditions, the 20S pro-
teasome, the PA700 and PA28 (700- and 180-kD pro-
teasome activator complexes, respectively), ubiquitin, 
Hsp70 and Hsp90 (70- and 90-kD heat shock protein, 
respectively) concentrate in HEK 293 and HeLa cells. 
The structure is perinuclear, surrounded by endoplas-
mic reticulum, adjacent to the Golgi, and colocalizes 
with 
 
g
 
-tubulin, an established centrosomal marker. 
Density gradient fractions containing purified cen-
trosomes are enriched in proteasomal components and 
cell stress chaperones. The centrosome-associated 
structure enlarges in response to inhibition of protea-
some activity and the level of misfolded proteins. For 
example, folding mutants of CFTR form large inclu-
sions which arise from the centrosome upon inhibition 
of proteasome activity. At high levels of misfolded pro-
tein, the structure not only expands but also extensively 
recruits the cytosolic pools of ubiquitin, Hsp70, PA700, 
PA28, and the 20S proteasome. Thus, the centrosome 
may act as a scaffold, which concentrates and recruits 
the systems which act as censors and modulators of the 
balance between folding, aggregation, and degradation.
Key words: proteasome • protein misfolding • inclu-
sions • CFTR • centrosome
M
 
any
 
 pathologies result from the inability of a mu-
tant protein to properly fold (Thomas et al.,
1995). It is therefore important to understand
the mechanisms by which misfolded proteins are recog-
nized, processed, and ultimately degraded by the cell. The
26S proteasome catalyzes the intracellular degradation of
damaged or misfolded proteins, the rapid degradation of
short-lived regulatory proteins such as those involved in
cell cycle control and signaling, as well as the generation of
antigenic peptides for presentation to MHC-I (Coux et al.,
1996). Degradation of most substrates by the proteasome
requires the covalent conjugation of ubiquitin, an event
catalyzed by the sequential action of three enzymes
(Ciechanover, 1994; Hochstrasser, 1996). The ubiquitina-
tion machinery acts progressively, resulting in a polyubiq-
uitin chain that serves as a signal for degradation of the
modified protein by the 26S proteasome.
The 26S proteasome is composed of two major subcom-
plexes. The 20S proteasome, a 700-kD cylinder, consti-
tutes the catalytic core of the protease (Coux et al., 1996;
Baumeister et al., 1998). Structural (Lowe et al., 1995;
Groll et al., 1997) and biochemical evidence (Wenzel and
Baumeister, 1995) indicate the catalytic sites are located
within a hollow cavity of the cylinder. Access to these sites
is achieved through narrow openings at the ends of the cyl-
inder which may be gated by regulatory proteins. This to-
pology limits substrates to short peptides and completely
unfolded proteins.
The regulatory complex of the 26S proteasome is a 20-
subunit, 700-kD activator called PA700
 
1
 
 or 19S cap (Coux
 
et al., 1996), which associates with either (or both)
end(s) of the 20S proteasome to form the 26S complex
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Abbreviations used in this paper: 
 
20S, 20S proteasome; cAMP, adeno-
sine 3
 
9
 
,5
 
9
 
-cyclic monophosphate; CF, cystic fibrosis; CFTR, cystic fibrosis
transmembrane conductance regulator; Hsp70/Hsp90, heat shock protein
(70 and 90 kD, respectively); NBD, nucleotide binding domain; PA700/
PA28, proteasome activator complex (700 and 180 kD, respectively);
PKA, cAMP-dependent protein kinase; SCA1, type-1 spinocerebellar
ataxia; TMD, transmembrane domain; Ub, ubiquitin; TBS-T, tris-buffered
saline/0.1% Tween-20.
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(Yoshimura et al., 1993; Coux et al., 1996; Adams et al.,
1997). Such binding probably activates proteasome func-
tion by opening access to the central cavity, thereby in-
creasing access of substrates to the catalytic sites. PA700
has multiple ATPase activities (Coux et al., 1996), binds to
and cleaves polyubiquitin (Lam et al., 1997), and functions
to enhance degradation of proteins, perhaps by unfolding
and/or translocating its substrates to the central cavity (Ma
et al., 1994; Adams et al., 1997).
A second regulator of the 20S proteasome is PA28 or
11S, a 180-kD heterohexameric ring-shaped complex that
binds to the proteasome in an orientation similar to that of
PA700 (Dubiel et al., 1992; Ma et al., 1993; Gray et al.,
1994). PA28 does not require ubiquitinated substrates for
activity and functions to increase proteasomal processing
of short peptides rather than larger proteins in vitro. Syn-
thesis of PA28 is stimulated by 
 
g
 
-interferon, implicating its
probable functional importance in antigen production and
presentation (Realini et al., 1994; Ahn et al., 1995; Dick
et al., 1996). New data suggest the proteasome may exist in
vitro in a complex simultaneously with PA28 and PA700,
although the physiological relevance of such an observa-
tion is unclear (Hendil et al., 1998).
A role has been established for the proteasome in the
degradation of incompletely folded or misfolded proteins
(Kopito, 1997). For example, both cystic fibrosis (CF)-
causing mutant forms (Riordan et al., 1989) and up to 70%
of the wild-type cystic fibrosis transmembrane conduc-
tance regulator (CFTR) (Ward and Kopito, 1994; Jensen
et al., 1995; Ward et al., 1995) have been shown to be de-
graded in an ATP-dependent, ubiquitin/proteasome-medi-
ated manner (Jensen et al., 1995; Ward et al., 1995). CFTR
is a member of the ATP-binding cassette (ABC) super-
gene family of membrane transport proteins (Higgins,
1992), and consists of five domains, including two nucle-
otide binding domains (NBD1 and NBD2), two trans-
membrane domains (TMD1 and TMD2), and a PKA-sen-
sitive regulatory domain (R) (Riordan et al., 1989).
Notably, of the more than 800 CF-causing CFTR muta-
tions identified to date, several initiate the CF pathology
by affecting the ability of the nascent polypeptide to fold
into a functional, stable native state (Qu et al., 1997). One
such mutation, the deletion of phenylalanine 508 (
 
D
 
F508)
is by far the most common, accounting for 
 
z
 
70% of the
disease causing alleles (Tsui, 1992). This mutation, located
in NBD1, results in a folding defective protein which is in-
completely glycosylated and fails to efficiently traffic to
the apical membrane (Cheng et al., 1990), and is degraded
by the proteasome (Jensen et al., 1995; Ward et al., 1995).
Several other CF-causing folding mutations (Gregory et al.,
1991; Sheppard et al., 1996) including P205S which is lo-
cated in the third membrane spanning helix (Wigley et al.,
1998) of TMD1, also result in inefficient processing and
maturation and increased degradation.
Significantly, both the 
 
D
 
F508 and P205S folding mutants
are functional when they assume a native conformation,
thus raising the possibility that overcoming the maturation
deficiency by correcting the underlying folding defect or
by circumventing a proteolytic recognition step may be of
therapeutic benefit. Unfortunately, inhibition of the pro-
teasome in HEK 293 cells expressing either wild-type or
 
D
 
F508 CFTR results in the accumulation of polyubiquiti-
 
nated CFTR including insoluble, perhaps aggregated, spe-
cies (Jensen et al., 1995; Ward et al., 1995).
Heat shock proteins, such as Hsp70 and Hsp90, have
been shown to play a role in both preventing protein ag-
gregation and promoting folding or degradation of a wide
range of proteins. Recently, the ubiquitination of certain
proteins has been shown to depend upon Hsp70, implicat-
ing it in the targeting of misfolded or mutant proteins for
degradation by the proteasome (Bercovich et al., 1997). In
this regard, Hsp70 has been shown to interact transiently
with immature, incompletely folded CFTR (Yang et al.,
1993). While this paper was under review, a report ap-
peared that demonstrated that the Hsp90 inhibitor geldana-
mycin prevents the association of immature CFTR with
the chaperone, blocks its maturation, and enhances its
degradation by the proteasome (Loo et al., 1998).
In spite of the large body of evidence demonstrating the
proteasome machineryÕs involvement in the degradation
of a diverse range of substrates, it is unclear whether its
functions are distributed homogeneously throughout the
cell or if they are segregated. We present evidence herein
of the centrosome as a unique location in which the pro-
teasome machinery, Hsp70, and Hsp90 are concentrated
in resting HEK 293 and HeLa cell lines. In addition, the
centrosome, a structure thought previously to function pri-
marily during cell division, responds to inhibition of the
proteasome and increases in the level of misfolded pro-
teins by expanding and recruiting cellular pools of the pro-
teasome components and Hsp70.
 
Materials and Methods
 
Materials
 
Plasmids pCMVNot6.2 and pCMVNot6.2-
 
D
 
F containing expressible hu-
man CFTR cDNAs were the generous gift of Dr. Johanna Rommens (The
Hospital For Sick Children, Toronto). Two anti–human (COOH termi-
nus) CFTR antibodies were used: mouse monoclonal antibody 24-1 from
Genzyme Diagnostics and rabbit polyclonal antibody R3194 (Zeng et al.,
1997). Mouse monoclonal anti–rat Grp78 (BiP) was obtained from Stress-
Gen Biotechnologies Corp. Monoclonal anti-ubiquitin and anti–
 
g
 
-tubulin
antibodies and rhodamine-conjugated wheat germ agglutinin were pur-
chased from Sigma Chemical Co. Mouse monoclonal anti-Hsp70 and anti-
Hsp90 antibodies were from Affinity Bioreagents, Inc. Goat polyclonal
anti-aldolase was from Biodesign International. Mouse monoclonal anti–
lamin B
 
1
 
 antibody was from Zymed Laboratories, Inc. Mouse monoclonal
anti–
 
b
 
-cop antibodies contained in media from secreting hybridoma cells
were the generous gift of Dr. George Bloom (Department of Cell Biology,
University of Texas Southwestern Medical Center). Fluorescein-conju-
gated concanavalin A was from Molecular Probes, Inc. Fluorescently la-
beled secondary antibodies were from Jackson ImmunoResearch Labora-
tories, Inc. Lactacystin was purchased from Calbiochem. All other
materials were of the highest quality commercially available.
 
Generation and Characterization of Antisera
 
Polyclonal anti-PA28 (Ma et al., 1993), anti–PA28-
 
a
 
 (Song et al., 1996),
and anti-20S proteasome (Ma et al., 1994) were generated as described.
Polyclonal antibodies were prepared in chickens against highly purified
bovine PA700. Chicken IgY was purified from egg yolks of immunized
birds. The antibodies specifically recognized multiple subunits of the
PA700 complex, including p112, p97, p58, p56, and p45, upon Western
blot analysis of crude cell lysates and could specifically immunoprecipitate
PA700 from solution using an agarose bound anti-IgY antibody. Poly-
clonal antibodies were prepared in rabbits against an HPLC-purified pep-
tide representing the 16 COOH-terminal amino acids of human p31
(Nin1p), a subunit of PA700 (Kominami et al., 1995).
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Preparation of P205S Mutant Expression Construct
 
Oligonucleotide-directed mutagenesis as described (Andrews and Lesley,
1998) was used to generate the mutant CFTR from the parent expression
vector pCMVNot6.2. In brief, mutants were selected based upon the in-
corporation of a second-site mutation in 
 
b
 
-lactamase which alters its sub-
strate specificity leading to resistance of transformed bacteria to cefo-
taxime and ceftriaxone in addition to ampicillin. The sequence of the
mutagenic primer used to create P205S was 5
 
9
 
-CGTGTGGATCGCT-
TCTTTGCAAGTGGC-3
 
9
 
. Incorporation of the mutation was verified by
DNA sequencing. Transfection-quality plasmid DNA was prepared using
reagents supplied by Qiagen Inc.
 
Cell Culture and Transfection
 
Wild-type and mutant CFTR cDNAs were transfected into human embry-
onic kidney (HEK) 293 or HeLa cells (American Type Culture Collec-
tion) using the Fugene Mammalian Transfection Reagent (Boehringer
Mannheim). Cell lines were maintained in DME supplemented with 10%
FCS, 50 
 
m
 
g/ml streptomycin, and 50 units/ml penicillin.
 
Preparation of Centrosomes
 
Centrosomes were isolated from HEK 293 and HeLa cells by discontinu-
ous gradient ultracentrifugation according to the method of Moudjou and
Bornens (1998). In brief, cells in the exponential phase of growth were
treated with 1 
 
m
 
g/ml cytochalasin D and 0.2 
 
m
 
M nocodazole for 1 h. Cells
were collected by trypsinization and centrifugation and the resulting pellet
was washed in TBS followed by 0.1
 
3
 
 TBS/8% sucrose. Cells were resus-
pended in 2 ml of 0.1
 
3
 
 TBS/8% sucrose followed by addition of 8 ml lysis
buffer (1 mM Hepes, pH 7.2, 0.5% NP-40, 0.5 mM MgCl
 
2
 
, 0.1% 
 
b
 
-mercap-
toethanol, 1 
 
m
 
g/ml leupeptin, 1 
 
m
 
g/ml pepstatin, 1 
 
m
 
g/ml aprotinin, and 1 mM
PMSF). The suspension was gently shaken and passed five times through
a 10-ml narrow-mouth serological pipette to lyse the cells. The lysate was
spun at 2,500 
 
g
 
 for 10 min to remove swollen nuclei, chromatin aggregates,
and unlysed cells. The resulting supernatant was filtered through a nylon
membrane followed by addition of Hepes buffer and DNase 1 to a final
concentration of 10 mM and 1 
 
m
 
g/ml, respectively, and incubated on ice
for 30 min. The mixture was gently underlaid with 1 ml of 60% sucrose so-
lution (10 mM Pipes pH 7.2, 0.1% Triton X-100, and 0.1% 
 
b
 
-mercaptoeth-
anol containing 60% [wt/wt] sucrose) and spun at 10,000 
 
g
 
 for 30 min to
sediment centrosomes onto the cushion. The upper 8 ml of the superna-
tant was removed and the remainder, including the cushion, containing
the concentrated centrosomes was gently vortexed and loaded onto a dis-
continuous sucrose gradient consisting of 70, 50, and 40% solutions from
the bottom, respectively, and spun at 120,000 
 
g
 
 for 1 h. Fractions were col-
lected and stored at –70
 
8
 
C before further analysis.
 
SDS-PAGE and Western Blotting
 
Density gradient fractions were diluted into 1 ml of 10 mM Pipes, pH 7.2,
and centrosomes were sedimented at 14,000 rpm in a microfuge for 15 min
at 4
 
8
 
C. Centrosome pellets were resuspended in Laemmli sample buffer
containing 5% 
 
b
 
-mercaptoethanol and electrophoresed on 10% SDS-
PAGE gels. Proteins were transferred onto nitrocellulose membranes in
the presence of Towbin transfer buffer (25 mM Tris, 192 mM glycine, and
20% methanol, pH 8.3). Membranes were blocked in TBS-T (Tris-buff-
ered saline/0.1% Tween-20) containing 10% nonfat dry milk for 1 h and
then incubated in fresh blocking buffer containing primary antibody at the
desired concentration. Membranes were washed several times in TBS-T
followed by incubation with the appropriate horseradish peroxidase–con-
jugated secondary antibody. Immunoreactive proteins were visualized
with enhanced chemiluminescence.
 
Inhibition of 20S Proteasome
 
The proteolytic activity of the endogenous proteasomal pool was inhibited
by the addition of the potent fungal product lactacystin. The inhibitor
was added to 293 cells 48–72 h after transfection at a concentration of
10 
 
m
 
M. Treatment of cells was carried out for 2 to 12 h and was immedi-
ately followed by several washes with PBS before fixation for immunocy-
tochemistry.
 
Immunocytochemistry
 
For immunofluorescent subcellular localization of CFTR (Lee et al.,
1997), transiently transfected cells attached to glass coverslips were rinsed
three times with PBS followed by fixation and permeabilization with 1 ml
of ice-cold methanol for 10 min at –20
 
8
 
C. Upon removal of methanol, cells
were again rinsed three times with PBS and incubated 10 min in 1 ml of
PBS supplemented with 50 mM glycine (this and all subsequent manipula-
tions were carried out at room temperature). This buffer was then re-
moved and nonspecific sites were blocked with 0.1 ml of blocking medium
(PBS supplemented with 5% goat serum, 1% BSA, and 0.1% gelatin) for
1 h in a humidified chamber. After blocking, the medium was replaced
with 0.1 ml of blocking medium containing a 1/100 dilution of the respec-
tive primary antibody for 1 h. Cells were next washed three times with
blocking medium and incubated for 1 h with blocking medium containing
a 1/100 dilution of the appropriate fluorescently labeled secondary anti-
body. For double-labeling experiments, these primary and secondary in-
cubations were repeated with antibodies against the second protein of in-
terest. For lectin affinity staining involving either fluorescently tagged
wheat germ agglutinin or concanavalin A, these reagents were added at
either a 1/250 dilution with the secondary antibody, or at 1 
 
m
 
g/ml in PBS
for 30 min before the initial fixation and permeabilization, respectively.
Fluorescent images were obtained using a Bio-Rad MRC 1024 confocal
microscope. Expression levels of cells expressing CFTR were divided into
two categories, those which required a gain of 1,150 or higher to visualize
(low expressers) and those which required a gain setting of 950 or less
(high expressers). In each case the Iris was held constant at 3.5. CMV-
driven CFTR expression levels can be categorized as either low or high.
At the high expression level, some cells form CFTR inclusions without
lactacystin treatment. This is observed for the folding mutants as well as
for wild-type CFTR. This is likely due to an overload of the cellular fold-
ing machinery and may account, in part, for the low (
 
z
 
30%) maturation
efficiency observed for wild-type CFTR overexpressed in cultured cells
(Ward and Kopito, 1994). We have therefore restricted our study to cells
expressing low levels of CFTR.
 
Subcellular Morphometry
 
Due to periodic irregularities in the shape of the perinuclear structure,
morphometric analysis describing their apparent diameter, as delineated
by confocal imaging of immunostained HEK 293 cells, was limited to cells
containing reasonably symmetric centrosomes. Measurements of diameter
were performed using software supplied by the manufacturer. Three fields
(
 
3
 
400) of each experiment were randomly selected and the diameters
were measured from all the cells in each field. In the case of elliptically
shaped structures, the geometric mean of the diameters were used. Data
presented are reported as the mean 
 
6
 
 SEM.
 
Analysis of Soluble and Insoluble Cellular Fractions
 
2.5 
 
3
 
 10
 
5
 
 HeLa cells per 3-cm dish were either mock-transfected or trans-
fected with P205S mutant CFTR expression plasmid. 48 h post-transfec-
tion, one of each was treated with 10 
 
m
 
M lactacystin for 12 h. Cells were
washed with PBS, collected by trypsinization, and pelleted in a microfuge
at 4
 
8
 
C. Each pellet was washed twice with PBS and resuspended in 100 
 
m
 
l
PBS supplemented with Complete protease inhibitor cocktail (Boehringer
Mannheim). After lysis by passage 10–20 times through a 27-gauge nee-
dle, lysates were spun at 14,000 
 
g
 
 for 1 h at 4
 
8
 
C. The supernatants were
collected and the pellets were washed in supplemented PBS followed by
centrifugation at 14,000 
 
g
 
 for 30 min. After aspiration of the wash solu-
tion, the pellets were resuspended in 100 
 
m
 
l supplemented PBS. Both pel-
lets and supernatants were stored at –70
 
8
 
C until analysis. Equal volumes
of each pellet and supernatant were analyzed by SDS PAGE through
4–20% gels followed by Western immunoblotting versus the indicated an-
tibodies as described above.
 
Results
 
Concentration of Proteasome Machinery at
the Centrosome
 
A central question with respect to proteasome-mediated
degradation of misfolded integral membrane proteins is
where in the cell does proteolysis occur. To address this
question, we employed immunocytochemistry to delineate
the subcellular distribution of several key components of
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the proteasome pathway including: the 20S proteasome,
the PA700 and PA28 activator complexes, ubiquitin, and
Hsp70.
 
In HEK 293 cells, antibodies directed against each of
these proteasome components identified multiple distinct
subcellular pools. The 20S proteasome (Fig. 1, A and D),
the PA700 complex (Fig. 1, B and E), and ubiquitin (Fig. 1
G) are each clearly discernible in both a nuclear pool and
a cytoplasmic pool. In contrast, PA28-associated immu-
nofluorescence was identified mainly in the nucleus (Fig.
1, C and F), and Hsp70 was primarily found in a reticular
pattern in the cytosol (Fig. 1 H). In addition to these gen-
eral distributions, staining with each of these specific anti-
bodies revealed the existence of a unique perinuclear site
in which all of the studied components concentrate (Fig. 1,
A—H). The structure is surrounded by but does not colo-
calize with staining against the ER lumenal chaperone BiP
(Fig. 1 F), and is proximal to the Golgi apparatus as illus-
trated by staining with the lectin, WGA (Fig. 1, D and E).
These same subcellular distributions were also observed in
HeLa, COS, and CHO cells suggesting generality of the
observation (data not shown).
Further investigation of this perinuclear structure using
double-labeled immunofluorescence revealed exact colo-
calization of the 20S proteasome, PA700, PA28, ubiquitin,
and Hsp70 with 
 
g
 
-tubulin, an established centrosomal
marker (Mitchison and Kirschner, 1984; Oakley and Oak-
ley, 1989). The majority of 
 
g
 
-tubulin staining was re-
stricted to the centrosome, although an expected faint dif-
fuse cytosolic staining was also observed corresponding to
the soluble fraction of this protein. These data implicate
the centrosome as a unique site for the colocalization and
concentration of the proteasomal machinery and certain
cell stress chaperones under basal conditions, suggesting a
novel function for the centrosome.
The specificity of these proteasomal antibodies for im-
munocytochemistry is supported by several control experi-
ments. First, using indirect immunofluorescence and con-
focal microscopy, staining with non- and preimmune
rabbit sera or secondary antibody alone revealed virtually
Figure 1. Localization of
proteasome components at
the centrosome. HEK 293
cells were immunostained
with antibodies against (A
and D) 20S proteasome and
g-tubulin (A) or fluores-
cently labeled WGA (D). (B
and E) PA700 and g-tubulin
(B) or fluorescently labeled
WGA (E). (C and F) PA28
and g-tubulin (C) or BiP (F).
(G) Ubiquitin (Ub) and
g-tubulin, and (H) Hsp70
and fluorescently labeled
WGA. Confocal images were
obtained as described under
Materials and Methods.
Specificity of antisera was in-
vestigated by staining HEK
293 cells with (I) polyclonal
chicken anti-PA700, or (J)
polyclonal chicken anti-
PA700, preabsorbed at room
temperature against purified
bovine PA700. Confocal flu-
orescent images were ob-
tained on the same day at
identical magnification, iris
settings, and gain. Note: For
clarity of presentation in
each panel, immunofluores-
cence of the proteasomal ma-
chinery, Hsp70, and Ub is
consistently presented in green
while the counter staining for
g-tubulin, WGA, and BiP is
consistently presented in red.
Arrows in panels A—H indi-
cate locations of perinuclear
proteasome-enriched centro-
somes. Scale bars indicate
size in mm.
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no detectable signal (data not shown). Second, preabsorp-
tion of chicken anti-PA700 antiserum against purified an-
tigen completely eliminated immunocytochemical fluores-
cence (Fig. 1, I and J). Likewise, a similar preabsorption of
rabbit anti-PA28 and Western blot analysis demonstrated
the specificity of this antisera. And third, staining with
anti-p31, a rabbit polyclonal antibody directed against a
single subunit of PA700, yielded a staining pattern that is
indistinguishable from that generated with the chicken
anti-PA700 complex antibodies. Similarly, staining with
polyclonal antisera raised against a peptide from the 
 
a
 
subunit of PA28 (Song et al., 1996) was identical to that
obtained with whole anti-PA28 (data not shown).
To confirm our immunocytochemical observations, cen-
trosomes were purified from nocodazole/cytochalasin
D—treated HEK 293 and HeLa cells by sucrose gradient
ultracentrifugation and subjected to Western blotting (Fig.
2). Analysis of the final purification step revealed a peak
of 
 
g
 
-tubulin immunoreactivity in fractions 3 through 6 cor-
responding to sucrose densities of between 50 and 60%. In
agreement with the immunocytochemical data, 20S pro-
teasome, p31 (PA700), PA28, and Hsp70 were observed in
fractions containing 
 
g
 
-tubulin, indicating their copurifica-
tion with the centrosome in the absence of an intact cy-
toskeleton. In addition, Hsp90 also copurified with 
 
g
 
-tubu-
lin. Interestingly, Hsp70, Hsp90, and to a lesser extent
 
PA28, were also observed in lighter gradient fractions,
where faint 
 
g
 
-tubulin immunoreactivity was detected. This
observation may be explained either by a heterogeneous
population of centrosomes or lower-affinity binding of the
chaperones and PA28 to the centrosome relative to that of
20S and PA700. Sucrose fractions were devoid of other
subcellular markers, including BiP (ER), aldolase (cyto-
sol), Lamin B
 
1
 
 (nucleus), and 
 
b
 
-cop (Golgi), establishing
the purity of the centrosome preparations.
 
Expansion of the Centrosome in Response to 
Proteasome Inhibition
 
Treatment of cells with lactacystin, a potent and specific
inhibitor of the proteasome (Fenteany et al., 1995) re-
sulted in a significant increase in size of the centrosome.
Representative images of cells treated and untreated with
lactacystin, were stained for PA28 and the lectin Con A
(Fig. 3, A and B). Similar results were obtained for cells
stained for 20S proteasome, Ub, PA700, Hsp70, and 
 
g
 
-tubu-
lin. These results were quantified by morphometric analy-
sis of centrosome diameters (identified by fluorescent
staining for 
 
g
 
-tubulin or perinuclear proteasomal compo-
nents). Comparison of lactacystin-treated and untreated
HEK 293 cells revealed a twofold increase in mean diame-
ter in response to the proteasome inhibition (Fig. 3 C).
These data suggest that the centrosome is a dynamic struc-
ture, capable of expansion in response to inhibition of the
proteasome. This expansion may be due to a build up of
misfolded proteins, which would otherwise be degraded by
the proteasome concentrated at the centrosome. To fur-
ther test this hypothesis, we expressed in HEK 293 cells
wild-type CFTR and two variants known to misfold,
namely 
 
D
 
F508 and P205S, and examined their effect on
the centrosome and the proteasome machinery.
 
Expansion in Response to Expression of Mutant Protein
 
Consistent with previous reports (Cheng et al., 1990), im-
munolocalization of CFTR in transiently transfected HEK
293 cells clearly differentiates the wild-type CFTR subcel-
lular locale from that of the folding mutants. Antiserum
directed against the COOH terminus of CFTR recognized
wild-type CFTR at the plasma membrane of transfected
cells (Fig. 4 A) and at an early stage of maturation that
colocalized with the ER-resident chaperone BiP (Fig. 4
B). The ER is the site of initial membrane translocation
and integration of nascent polytopic membrane proteins.
In sharp contrast, 
 
D
 
F508 and P205S mutant CFTR are de-
tected predominantly in the ER of transfected cells as il-
lustrated by the ER pattern of CFTR staining (Fig. 4, C
and E) and the complete colocalization with BiP staining
(Fig. 4, D and F).
 
Cells expressing low levels of the wild-type CFTR do
not significantly perturb either the PA28 distribution or
size of the centrosome, although in highly expressing cells
a fraction of CFTR colocalizes within this structure as seen
in Fig. 5 A. Similar results were obtained with other pro-
teasome components studied (data not shown). In striking
contrast, expression of P205S (Fig. 5 B) or 
 
D
 
F508 (data not
shown) expands the centrosome in a manner similar to
that observed when cells are treated with lactacystin alone
(Fig. 3). This observation provides further support for the
Figure 2. Proteasomal components and heat shock proteins
cosediment with g-tubulin on a sucrose gradient. Centrosomes
were prepared from 7 3 107 293 cells and fractions were collected
from a discontinuous sucrose gradient as detailed in Materials
and Methods. Equal amounts of individual fractions were sub-
jected to Western blot analysis. Fractions 1—10 are the gradient
fractions collected from the bottom up, i.e., 70—30% sucrose. W
indicates 10 mg of whole cell lysate as a control for each blot. BiP,
aldolase, lamin B1, and b-cop, the markers for ER lumen, cytosol,
nucleus and Golgi, respectively, are detected only in whole cell
lysates, but not in centrosome fractions, establishing the purity of
the centrosome prep. Sizes of each protein are denoted in kD.
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accumulation of misfolded proteins at the site of the cen-
trosome even when the proteasome is functional.
 
Recruitment of Proteasomal Components to a 
Centrosome-Associated Inclusion
 
In cells overexpressing mutant CFTR (P205S) and treated
with lactacystin, we observed the formation of large, peri-
nuclear aggregates of misfolded CFTR which appear to
arise from the centrosome as indicated by colocalization
with 
 
g
 
-tubulin (Fig. 6). Identical results were observed
with 
 
D
 
F508 expressing cells (data not shown). In addition,
a remarkable and comprehensive recruitment of the cyto-
solic pools of the 20S proteasome (Fig. 7 A), PA700 (B),
ubiquitin (D), and Hsp70 (E) to the site of CFTR aggre-
gate formation was observed. This recruitment is coinci-
dent with a depletion of the cytosolic pools implicating this
as the source. PA28 is also recruited to the inclusion in re-
sponse to the build up of misfolded CFTR (Fig. 7 C). Mor-
phometric analysis of the CFTR aggregate formed in lac-
tacystin treated cells is presented in Fig. 7 F. A composite
of data from Fig. 3 E describing centrosome expansion due
to proteasome inhibition alone relative to nontreated cells
is included for comparison. The diameter of the aggregate
formed in lactacystin-treated cells expands to four to six
times the size of the centrosome from which it is appar-
ently derived.
 
Next, to further investigate the observed redistribution
of the proteasomal machinery and Hsp70 in response to
the formation of lactacystin-induced intracellular inclu-
sions of misfolded CFTR, we separated cell lysates into
soluble and insoluble cellular fractions. In mock-trans-
fected cells, 
 
g
 
-tubulin was observed primarily in the solu-
ble fraction (Fig. 8). However, in cells expressing P205S
mutant CFTR and treated with lactacystin, 
 
g
 
-tubulin was
observed distributed between the soluble and insoluble
fractions. PA28, PA700, and Hsp70 redistributed in a man-
ner parallel to 
 
g
 
-tubulin (Fig. 8). An intermediate degree
of redistribution was observed for mock-transfected cells
treated with lactacystin and untreated mutant transfected
cells (data not shown).
 
Discussion
 
The work reported here describes the immunocytochemi-
cal (Fig. 1) and biochemical (Fig. 2) identification of the
centrosome as a unique subcellular location in which, un-
der basal conditions, components of the proteasome pro-
teolytic pathway and certain relevant heat shock chaper-
ones concentrate. This localization was observed under
normal growth conditions in HEK 293, HeLa, COS, and
CHO cells. Moreover, the association of the proteasome
with the centrosome does not require an intact F-actin nor
microtubular network as indicated by their presence in the
purified centrosomal fractions obtained from nocodazole/
cytochalasin D–treated cells (Fig. 2), indicating that their
localization at this site is not simply a result of clustering at
the minus-ends of microtubules. This does not, however,
exclude the possibility that the cytoskeleton may be re-
quired for trafficking to and from this location.
 
When the cellular level of misfolded protein is high, ei-
ther due to the overexpression of a misfolded mutant pro-
tein (such as 
 
D
 
F508 or P205S CFTR) or the inhibition of
the proteasome, the cell responds by expanding the diame-
Figure 3. The centrosome expands in response to proteasome inhibition. (A and B) HEK
293 cells were stained with antibodies against PA28 (green) and fluorescently labeled Con
A (red). Cells in B were treated with 10 mM lactacystin as described in Materials and Meth-
ods. Arrows in each panel indicate the location of representative centrosomes. Scale bars
are in mm. (C) Morphometric measurements quantifying and comparing apparent cen-
trosome diameter of lactacystin-treated (1) and control cells (2), as stained with antisera
against the indicated proteins, is presented as the mean 6 SEM of 9—16 determinations.
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ter of the centrosome up to twofold (Figs. 3 and 5). As-
suming a spherical, three-dimensional shape, this would
translate to more than a fourfold increase in its volume.
Under high loads of misfolded substrate and/or insuffi-
cient proteasome activity, the centrosome, Hsp70, and the
proteolytic machinery undergo correspondent redistribu-
tion to a sedimentable fraction (Fig. 8). The presence of
the perinuclear proteasome concentration in control cells
argues that the simplest explanation for this expansion in-
volves the targeting of misfolded proteins to this central-
ized locale for rapid and efficient degradation. Consistent
with this hypothesis, the centrosomal-associated proteaso-
mal machinery is active (Fabunmi, R.P., W.C. Wigley, P.J.
Thomas, and G.N. DeMartino, unpublished observations).
When degradation is insufficient the misfolded proteins
accumulate at and proximal to this site eventually forming
a large inclusion. In light of this finding and the proximity
of the centrosome to the Golgi and lysosomes, care should
be taken when interpreting subcellular localization of
overexpressed proteins.
It is particularly interesting that under the highest loads
of misfolded protein, when the proteasome is inhibited
and a mutant protein is overexpressed, the cell responds
by extensively recruiting additional proteasomal machin-
ery from the cytosolic pools to the centrosome-associated
inclusion (Fig. 7). The function of the centrosome in nu-
cleating and organizing microtubules (Mitchison and
Kirschner, 1984) suggests the involvement of microtubule-
Figure 4. Intracellular localization of CFTR by immunofluores-
cence. Transiently transfected HEK 293 cells expressing the indi-
cated CFTR constructs were stained with rabbit polyclonal anti-
CFTR followed by rhodamine-labeled goat anti—rabbit IgG, and
mouse monoclonal anti-BiP followed by fluorescein-labeled don-
key anti—mouse IgG. A and B, C and D, and E and F are pairs
from the same fields. Scale bars indicate size in mm.
Figure 5. Centrosomes expand in response to misfolded protein.
Transiently transfected HEK 293 cells expressing either wild-
type or mutant P205S CFTR (as indicated) were stained with
antibodies against CFTR (red) and either PA28 (A) or 20S pro-
teasome (B) (each in green). Arrows indicate the location of
centrosomes in cells expressing CFTR. Arrowheads indicate cen-
trosomes in nonexpressing cells from the same fields for relative
comparison. Scale bars are in mm.
Figure 6. Intracellular inclusions of misfolded proteins arise from
the centrosome. Cells expressing moderate levels of CFTR-
DF508 were treated with 10 mM lactacystin for 12 h and stained
with (A and C) rabbit polyclonal anti-CFTR followed by fluores-
cein-labeled goat anti—rabbit IgG and (B and D) mouse mono-
clonal anti—g-tubulin followed by rhodamine-labeled donkey
anti—mouse IgG. A and B, C and D are pairs from the same
fields. Arrows indicate g-tubulin—visualized centrosomes cen-
tered at the sites of mutant CFTR aggregate formation. The scale
bar indicates size in mm.
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based motors in the recruitment process. Consistent with
this notion is the observation that the nuclear pools of pro-
teasomal component remain unperturbed (Fig. 7). Further
experiments will be required to determine if the recruit-
ment is an active process or simply due to diffusion al-
though the latter possibility is unlikely because molecules
the size of the 26S proteasome are too large to simply dif-
fuse through the cytosol (Janson et al., 1996).
Similar questions exist as to the targeting of the sub-
strates to this site. While this manuscript was under re-
view, an interesting and complementary study reported
the formation of CFTR aggregates at the centrosomes
(Johnston et al., 1998). Formation of the aggregates
required an intact microtubular system implicating a mo-
tor-based translocation of substrate to the centrosome,
analogous to the potential mechanism of proteasome re-
cruitment suggested here. Interestingly, fibrillar exten-
sions, as observed by CFTR and proteasomal staining
(Figs. 6 A and 7), radiate from the centrosomally localized
aggregates. These fibrils are sensitive to treatment with
nocodazole suggesting their microtubular origin. How-
ever, the centrosomal localization of the aggregates and
associated proteasomal components persist in lactacystin
treated cells after nocodazole treatment. The mechanisms
employed for assembly and, potentially, disassembly of
these structures deserves further study. Regardless of the
means of assembly, it is clear that this structure concen-
trates and recruits proteins that would be expected to perform
Figure 7. Proteasome machinery is recruited
to CFTR aggregates. HEK 293 cells tran-
siently transfected with the indicated CFTR
expression construct were treated with 10 mM
lactacystin as described in Materials and
Methods. Cells were then stained with (A)
mouse monoclonal anti-CFTR (red), and rab-
bit polyclonal anti-20S proteasome (green),
(B) rabbit polyclonal anti-CFTR (red), and
chicken polyclonal anti-PA700 (green), (C)
mouse monoclonal anti-CFTR (red), and rab-
bit polyclonal anti-PA28 (green), (D) mouse
monoclonal anti-CFTR (red), and rabbit
polyclonal anti-ubiquitin (green), or (E) rab-
bit polyclonal anti-CFTR (red), and mouse
monoclonal anti-Hsp70 (green). Arrows in
each panel indicate cells whose cytosol has
been cleared of detectable proteasomal com-
ponents due to recruitment to centrosome-
associated inclusions. A morphometric analy-
sis of the relative expansion of the centrosome
and CFTR aggregates is presented in panel
(F). The expansion due to inhibition of the
proteasome with lactacystin alone and lacta-
cystin with low expression of wild-type,
DF508, and P205S CFTR was determined
from at least eight measurements. The
dashed line represents the relative size of an
untreated centrosome. Errors are 6 SD.
Scale bars indicate size in mm.
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a censor function by monitoring and perhaps controlling
the balance between folding, degradation, and aggregation
of nascent membrane proteins in the cell.
Understanding the composition and assembly of the
proteasome-enriched centrosomes should provide new in-
sight into the mechanisms of quality control employed by
eukaryotic cells. For example, it is unclear if PA700, free
or in complex with the 20S proteasome, participates di-
rectly in the recognition of the misfolded CFTR, altered
localization, or the formation of the inclusions. However,
it is possible that free PA700 uses its poly-Ub binding do-
mains and other cues to identify substrates not only for the
proteasome, but also for transport to the centrosome. Sub-
sequently or coincidentally, ATP-dependent association
with the 20S proteasome, PA700-mediated Ub isopepti-
dase activity, and other likely activities such as active un-
folding would then serve to reexamine the substrate and
perhaps, as an alternative to degradation, allow a second
attempt at folding before degradation. Such iterative steps
are known to occur in the Hsp60 class of chaperones
(Bukau and Horwich, 1998) and the Clp family of pro-
teases (Kessel et al., 1996).
The accumulation of overexpressed mutant CFTR at
the centrosome upon inhibition of proteolysis suggests
that it may serve as a terminal point in the pathway of mis-
folded polypeptides suggesting that they either assemble
or nucleate at this location. It is interesting to note that
similar inclusions (Russell, 1890; Valetti et al., 1991) have
been previously observed in heat-stressed (Vidair et
al., 1996), protease-inhibited cells (Wjcik et al., 1996;
Johnston et al., 1998), and a growing family of pathologies
related to protein misfolding such as AlzheimerÕs, Hun-
tingtonÕs, amyotrophic lateral sclerosis, and type-1 spino-
cerebellar ataxia (SCA1) (Bruijn et al., 1998; Cummings et
al., 1998; Sisodia, 1998). The detailed structural and func-
tional relationships among these inclusions are unknown
and warrants further investigation.
The centrosomal localization of the proteolytic machin-
ery under basal conditions described in this study may play
an important role in the degradation of proteins involved
in progression through the cell cycle (King et al., 1996). In
addition, this position also places the proteasome and
chaperones proximal to the cellular organelles directly in-
volved in the production, maturation, and trafficking of
membrane proteins, a strategic locale for machinery in-
volved in the recognition and processing of mutant pro-
teins. Interestingly, recent studies in yeast, which lack the
resolution of the current work, place the 26S proteasome
at either the nuclear envelope-endoplasmic reticulum
(Enenkel et al., 1998) or, in fission yeast, at the nuclear pe-
riphery at rest and in a nuclear-associated spot during mei-
osis (Wilkinson et al., 1998). Although the ER is generally
considered the quality control organelle, based on BiP,
WGA, and Con A staining, the current higher resolution
studies indicate that in mammalian cells the proteasome
concentrates in a compartment probably post-ER, lacking
the complex glycoproteins of the Golgi. Dissecting the bio-
chemical function of the centrosome should reveal if it is
the site of proteasome-mediated degradation of misfolded
and mutant membrane proteins. We are actively address-
ing these issues.
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